Monitor for regulatory feedback on the LT-100 clinical protocol and any subsequent study initiation announcement, which would be the next meaningful catalyst. Also watch for Series A preferred stock conversion completion as a de-risking event.
Price Chart
Executive Summary
Glucotrack (GCTK) issued a shareholder update via its Lkahi Therapeutics subsidiary, providing a strategic overview of its LT-100 osteoarthritis knee pain program, ai² platform expansion, and post-merger structure. No financial results, guidance, or material quantitative data were disclosed. The filing is a routine business update with no hard catalysts or financial figures.
Key Facts
- Clinical protocol for LT-100 (osteoarthritis knee pain) submitted for regulatory review; study initiation targeted in near term subject to regulatory feedback.
- Planned LT-100 study evaluates once-weekly subcutaneous injection vs. historical 15 weekly intradermal injections.
- ai² Pipeline network includes >14 university partners and screens >12,000 decommissioned/deprioritized/abandoned late-stage pharma programs.
- Over 45 assets met initial screening criteria in first year; preliminary business development discussions underway.
- Series A convertible preferred stock conversion remains subject to Nasdaq requirements and other conditions.
- Glucotrack Technologies continues as wholly owned subsidiary focused on CGM; parent company resources directed to Lkahi Therapeutics.
- Qare initiative being developed within ai² Accelerator framework, still in early stages.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- LT-100 remains pre-clinical; regulatory feedback could delay or require protocol changes.
- Series A preferred stock conversion still subject to Nasdaq requirements and conditions.
- No revenue or cash runway data provided; capital needs for clinical development unclear.
- Business model depends on acquiring and monetizing third-party assets, which carries execution risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043844 |
| Exhibit: ex99-1.htm | 0001493152-26-043844 |
| Document: 0001493152-26-043844-index-headers.html | 0001493152-26-043844 |
| Document: 0001493152-26-043844-index.html | 0001493152-26-043844 |
| Document: 0001493152-26-043844.txt | 0001493152-26-043844 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | — |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | S-1/A | $0.8873 | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | — |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | — |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers